Volume 35, Issue 10 pp. 969-971

Teicoplanin Pharmacokinetics During Albumin Dialysis

Stefan Weiler

Stefan Weiler

Clinical Pharmacokinetics Unit, Laboratory of Inflammation Research, Department of Internal Medicine I, Innsbruck Medical University

Search for more papers by this author
Gerda Falkensammer

Gerda Falkensammer

Central Institute for Medical and Chemical Laboratory Diagnostics, Innsbruck General Hospital

Search for more papers by this author
Christoph Seger

Christoph Seger

Central Institute for Medical and Chemical Laboratory Diagnostics, Innsbruck General Hospital

Search for more papers by this author
Michael Joannidis

Michael Joannidis

Medical Intensive Care Unit, Department of Internal Medicine I, Innsbruck Medical University, Innsbruck, Austria

Search for more papers by this author
Romuald Bellmann

Corresponding Author

Romuald Bellmann

Clinical Pharmacokinetics Unit, Laboratory of Inflammation Research, Department of Internal Medicine I, Innsbruck Medical University

Medical Intensive Care Unit, Department of Internal Medicine I, Innsbruck Medical University, Innsbruck, Austria

Prof. Dr. Romuald Bellmann, Department of Internal Medicine I, Innsbruck Medical University, A-6020 Innsbruck, Austria. E-mail: [email protected]Search for more papers by this author
First published: 19 April 2011
Citations: 2

Present address: Gerda Falkensammer, Medical Laboratory, Wels, Austria.

Abstract

Teicoplanin (TP) pharmacokinetics was assessed in a critically ill patient during albumin dialysis (AD), which was performed with the molecular adsorbent recirculating system. After a 1200-mg loading dose (24 mg/kg), doses of 1200 and 1000 mg (20 mg/kg) on day 2 and 3, respectively, were administered during two cycles of AD. The mean TP peak and trough concentrations amounted to 99.3 and 21.4 µg/mL, respectively, during AD. A mean half-life of 5.5 h, an apparent volume of distribution of 0.302 L/kg, and a mean total TP clearance of 39 mL/h/kg were calculated. Ninety minutes after the start of AD, the extracorporeal clearance was 3560 mL/h. Within 8 h of AD therapy, the serum concentrations decreased by about 75%. Despite a considerable elimination of TP by AD, therapeutic serum levels could be maintained during the entire treatment by administration of high doses and close monitoring of TP serum concentrations.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.